Mohsin Shah

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4047737/publications.pdf

Version: 2024-02-01

		1040056	839539
18	1,217	9	18
papers	citations	h-index	g-index
18	18	18	1988
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Very high <scp>PDâ€L1</scp> expression as a prognostic indicator of overall survival among patients with advanced <scp>nonâ€small</scp> cell lung cancer receiving antiâ€ <scp>PD</scp> â€(L)1 monotherapies in routine practice. Pharmacoepidemiology and Drug Safety, 2022, 31, 1121-1126.	1.9	6
2	Effect of anti–tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis—A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic. Journal of the American Academy of Dermatology, 2021, 84, 161-163.	1.2	13
3	Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians ShouldÂKnow. Annals of Emergency Medicine, 2020, 75, 264-286.	0.6	3
4	Association of cancer screening and residing in a coal-polluted East Asian region with overall survival of lung cancer patients: a retrospective cohort study. Scientific Reports, 2020, 10, 17432.	3.3	1
5	Diagnosis and management of immune $\hat{\epsilon}_{\mathbf{r}}$ elated adverse effects of immune checkpoint therapy in the emergency department. Journal of the American College of Emergency Physicians Open, 2020, 1, 1637-1659.	0.7	17
6	SARS-CoV-2 and Anti-Cardiolipin Antibodies. Clinical Medicine Insights: Case Reports, 2020, 13, 117954762098038.	0.7	8
7	Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Seminars in Arthritis and Rheumatism, 2019, 48, 736-740.	3.4	90
8	Serious immuneâ€related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review. Head and Neck, 2019, 41, 4036-4050.	2.0	3
9	Extramedullary Plasmacytoma Involving the Trachea: A Case Report and Literature Review. Journal of Emergency Medicine, 2019, 57, e65-e67.	0.7	6
10	Safety of Immune Checkpoint Blockade in Patients with Cancer and Preexisting Autoimmune Diseases and/or Chronic Inflammatory Disorders. Journal of Immunotherapy and Precision Oncology, 2019, 2, 59-64.	1.4	8
11	Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease. Annals of Internal Medicine, 2018, 168, 121.	3.9	341
12	Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease. Annals of Internal Medicine, 2018, 169, 133.	3.9	44
13	Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. PLoS ONE, 2016, 11, e0160221.	2.5	373
14	Intuitive weights of harm for therapeutic decision making in smear-negative pulmonary Tuberculosis: an interview study of physicians in India, Pakistan and Bangladesh. BMC Medical Informatics and Decision Making, 2014, 14, 67.	3.0	9
15	Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. Blood Cells, Molecules, and Diseases, 2012, 48, 199-201.	1.4	5
16	The physician's unique role in preventing violence: a neglected opportunity?. BMC Medicine, 2012, 10, 146.	5.5	6
17	Perceived Stress, Sources and Severity of Stress among medical undergraduates in a Pakistani Medical School. BMC Medical Education, 2010, 10, 2.	2.4	242
18	Self-reported tobacco smoking practices among medical students and their perceptions towards training about tobacco smoking in medical curricula: A cross-sectional, questionnaire survey in Malaysia, India, Pakistan, Nepal, and Bangladesh. Substance Abuse Treatment, Prevention, and Policy, 2010, 5, 29.	2.2	42